All In Biotech

Drug Trial Radar · NCT03999437

SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS

EFFICACY AND SAFETY OF A SINGLE-APPLICATION TREATMENT USING TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION TREATMENT USING BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Last checked: Nov 19, 2026Latest source record: Jun 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

42

Planned (sponsor's estimate)

Start

Jan 2, 2019

Primary completion

Dec 13, 2019

Study completion Jan 3, 2020

Sponsor

Lead sponsor
United LaboratoriesIndustry
Sponsor type
Industry
First posted
Jun 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Tinea pedis or athlete's foot is the most common fungal infection worldwide, caused by infection of the feet with dermatophytes such as Trichophyton rubrum, Trichophyton interdigitale (formerly Trichophyton mentagrophytes), and Epidermophyton floccosum. Diagnosis of tinea pedia involves clinical symptoms as well as microscopic examination. Topical therapies are usually applied once or twice daily for as long as 4 weeks, posing a challenge to compliance. The current study aims to test a formulation of the single-dose 1% terbinafine hydrochloride, as well as a single-dose 1% butenafine hydrochloride, versus a vehicle control in adult Filipino patients with athlete's foot. This study will benefit the Filipino community by helping us determine which anti-fungal cream is most effective for athlete's foot.

Conditions

  • Tinea Pedis

Interventions

  • TERBINAFINE HYDROCHLORIDE (1%)Drug

    Topical liquid solution

  • BUTENAFINE HYDROCHLORIDE (1%)Drug

    Topical liquid solution

  • Vehicle ControlDrug

    Topical liquid solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with effective treatment at week 6Time frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Management and Testing Associates, Inc.

    City of Muntinlupa, Philippines · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.